The Science Behind Peptide Therapy

What are peptides?

At the most basic level, peptides are short chains of amino acids — the same building blocks that make up proteins. While proteins can contain hundreds or thousands of amino acids folded into complex three-dimensional structures, peptides are typically between 2 and 50 amino acids long. This smaller size gives them specific properties: they can be more precisely targeted, they're often easier for the body to absorb and use, and they tend to have fewer off-target effects than larger, more complex molecules.

Your body naturally produces thousands of peptides. They function as signaling molecules — chemical messengers that tell cells what to do. Insulin, for example, is a peptide hormone. So are oxytocin, endorphins, and growth hormone-releasing hormone. Peptides regulate virtually every biological process: immune response, tissue repair, metabolism, reproduction, sleep, appetite, mood, and pain perception.

Therapeutic peptides are synthetic versions of these natural signaling molecules, designed to supplement or enhance your body's own peptide-based communication systems. They're not foreign chemicals — they're precise copies (or close analogs) of molecules your body already recognizes and uses.

How therapeutic peptides work in the body

Peptides work by binding to specific receptors on cell surfaces — like a key fitting into a lock. When a peptide binds to its receptor, it triggers a cascade of cellular events: genes are activated or silenced, proteins are produced, inflammatory processes are modulated, or other signaling molecules are released.

Because peptides are highly specific in which receptors they bind to, they can produce targeted effects with fewer side effects than many conventional drugs. A peptide designed to stimulate growth hormone release, for example, acts specifically on the receptors in the pituitary gland responsible for GH production. It doesn't broadly affect unrelated systems the way many pharmaceutical compounds do.

Most therapeutic peptides are administered via subcutaneous injection — a small needle into the fat just under the skin. This is because peptides, being short protein chains, would be broken down by digestive enzymes if taken orally (with some notable exceptions like BPC-157). Injectable administration allows the peptide to enter the bloodstream intact and reach its target receptors.

Once in the body, peptides are metabolized relatively quickly — broken back down into their amino acid components and recycled. This is actually a safety advantage: they don't accumulate in tissues the way some drugs do, and their effects are typically dose-dependent and time-limited.

The regulatory landscape: what you need to understand

The regulatory status of peptides is one of the most confusing and rapidly evolving areas in medicine right now. Understanding the basics will help you make informed decisions about your care.

FDA-approved peptides

Some peptides have gone through the full FDA approval process — Phase I, II, and III clinical trials demonstrating safety and efficacy for specific indications. These peptides have the strongest evidence base and the clearest regulatory status.

• Semaglutide (Ozempic/Wegovy): FDA-approved for type 2 diabetes and chronic weight management
• Tirzepatide (Mounjaro/Zepbound): FDA-approved for type 2 diabetes and weight management
• PT-141 / Bremelanotide (Vyleesi): FDA-approved for hypoactive sexual desire disorder in premenopausal women

These medications can be prescribed by any licensed physician for their approved indications, and can also be prescribed off-label when the physician determines it's clinically appropriate.

Category 1 peptides: legally compoundable

Category 1 peptides are those that the FDA has determined can be legally prepared by licensed compounding pharmacies. Compounding pharmacies create customized medications under the supervision of a pharmacist, following strict standards (USP 797/800). These peptides have sufficient safety data and clinical history to be compounded for individual patients under a physician's prescription.

• Sermorelin: Growth hormone-releasing hormone analog with decades of clinical use
• NAD+: Coenzyme critical for cellular energy and repair

Category 1 peptides have the clearest path for compounding. They can be prescribed by physicians and prepared by licensed pharmacies without regulatory ambiguity.

Category 2 peptides: under regulatory review

This is where it gets complicated. In 2023, the FDA began a review process to determine which peptides should be eligible for compounding. Peptides placed in Category 2 are those the FDA is still evaluating. During this review period, compounding of these peptides has been restricted in many cases.

• BPC-157: Extensive preclinical research for tissue repair and gut healing
• TB-500 (Thymosin Beta-4 fragment): Research on tissue repair and inflammation
• CJC-1295: Modified growth hormone-releasing hormone analog
• Ipamorelin: Selective growth hormone-releasing peptide

The Category 2 designation doesn't mean these peptides are dangerous — it means the FDA is still deciding whether they should be compoundable. Many of these peptides have been used clinically for years with favorable safety profiles. However, until the FDA completes its review and potentially reclassifies them, their availability through compounding pharmacies may be limited.

What's changing in 2026

The FDA's peptide review process is ongoing, and 2026 is expected to bring further clarity to the regulatory landscape. Several Category 2 peptides may be reclassified — either moved to Category 1 (compoundable) or formally restricted. The FDA has indicated it intends to complete this review process, which will provide more regulatory certainty for physicians, pharmacies, and patients.

Additionally, the regulatory environment around compounding of semaglutide and tirzepatide continues to evolve. As brand-name supply stabilizes and FDA enforcement actions continue, the availability of compounded versions of these medications may change. We monitor these developments closely and will always be transparent about what's available and what isn't.

The evidence base: an honest assessment

Not all peptides have the same level of evidence behind them. At Meridian, we believe in being transparent about what the research actually shows, so you can make informed decisions.

Meridian's evidence standards

We only offer peptides where the benefit-risk profile is supported by clinical or strong preclinical evidence and where our physicians are comfortable prescribing. This means:

• We don't offer every peptide that exists. There are dozens of peptides marketed online that we won't prescribe because the evidence isn't there or the risk profile isn't acceptable.
• We're honest about evidence levels. When a peptide has strong clinical trial data, we'll tell you. When the evidence is primarily preclinical, we'll tell you that too. You deserve to know the difference.
• We adapt as evidence evolves. Our formulary changes as new research is published and the regulatory landscape shifts. We add peptides when the evidence supports them and remove them if safety concerns emerge.
• Physician judgment is the final arbiter. Even for peptides we offer, your physician determines whether it's appropriate for your specific situation. Not every treatment is right for every patient.

Quality and testing: what actually matters

If you've researched peptides online, you've probably encountered research peptide vendors selling vials for a fraction of the price of medically prescribed peptides. The price difference exists for a reason — and understanding that reason is critical for your safety.

Medically prescribed peptides from licensed compounding pharmacies undergo rigorous quality control. Here's what that actually means:

HPLC purity analysis

High-Performance Liquid Chromatography (HPLC) is the gold standard for testing peptide purity. It separates the components of a sample and measures what percentage is the intended peptide versus impurities. Medical-grade peptides typically achieve 98–99% purity. Research-grade peptides from unregulated vendors may contain significant impurities — degradation products, incomplete synthesis fragments, or even entirely different compounds — that you'd never know about without independent testing.

Sterility testing

Injectable peptides must be sterile. This seems obvious, but achieving and verifying sterility requires specific facilities (clean rooms), equipment, and processes. Licensed compounding pharmacies follow USP 797 standards for sterile compounding — mandating specific environmental controls, personnel training, and testing protocols. Every batch is tested for microbial contamination before release. Unregulated vendors have no such requirement.

Endotoxin screening

Endotoxins are toxic compounds produced by certain bacteria. Even if a product is technically "sterile" (no live bacteria), it can still contain dangerous endotoxin levels if the manufacturing process wasn't properly controlled. Endotoxins can cause fever, inflammation, and in severe cases, septic shock. The LAL (Limulus Amebocyte Lysate) test is used to detect endotoxins at extremely low levels. Every batch of medical-grade injectable peptide is tested for endotoxins.

Potency verification

Potency testing confirms that the vial contains the amount of peptide stated on the label. This matters because dosing precision is important for both efficacy and safety. If a vial labeled "5mg" actually contains 3mg or 8mg, your dosing will be wrong — potentially leading to reduced efficacy or unexpected side effects. Licensed pharmacies verify potency as part of their batch release process.

Why this matters for you

When you purchase research peptides from an unregulated vendor, you have no guarantee of purity, sterility, potency, or endotoxin levels. You're injecting a substance into your body based on what a label says, without any independent verification. When your peptide is prescribed by a physician and compounded at a licensed pharmacy, every batch has been tested before it reaches you. The price difference reflects the cost of this quality assurance — and it's a cost worth paying when the product goes directly into your bloodstream.

The regulatory landscape in 2026

The regulation of compounded peptides is in a period of significant transition. Here's a clear summary of where things stand:

• Category 1 peptides (Sermorelin, NAD+, and others) have clear legal standing for compounding. Licensed pharmacies can prepare them under a physician's prescription. This is stable.
• Category 2 peptides (BPC-157, TB-500, CJC-1295, Ipamorelin, and others) are in regulatory limbo. The FDA has restricted their compounding while it completes a review process. The outcome could go either way — they may be moved to Category 1 (allowing compounding) or formally restricted.
• GLP-1 compounding is subject to ongoing FDA enforcement regarding semaglutide and tirzepatide. As brand-name supply and demand dynamics evolve, the compounding landscape for these medications continues to shift.
• State-level variation exists. Some states have taken independent positions on peptide regulation that differ from federal guidance. Your Meridian physician will navigate these complexities for you.

We believe this regulatory evolution is ultimately good for patients. Clearer rules mean more transparency, more quality control, and more protection for consumers. In the meantime, Meridian operates conservatively — we only prescribe peptides that are legally available through licensed compounding channels, and we're transparent when regulatory changes affect availability.

Why Meridian exists

Peptide therapy is real medicine with real potential. But the space has been muddied by hype, misinformation, and unregulated vendors selling unverified compounds. Patients deserve better than having to navigate this landscape alone.

Meridian exists to provide what this space needs most: physician oversight, pharmacy-grade quality, regulatory compliance, and honest communication about what peptides can and can't do. We're not going to tell you a peptide will change your life if the evidence says it might help. We're not going to prescribe something our physicians aren't comfortable with. And we're not going to hide behind vague language when we should be transparent about regulatory status, evidence levels, and realistic expectations.

That's the standard of care we believe in. It's less exciting than the marketing you'll find elsewhere. But it's honest — and when it comes to what you put in your body, honest is what matters.